Skip to main content
Conference Insider

What to Expect at PBMI’s 2020 National Conference

February 2020

The Pharmacy Benefit Management Institute (PBMI) is the nation’s leading provider of research and education that informs, advises, and influences the industry on drug cost management. PBMI’s offered insights enable evidence-based, actionable decision making in a complex and evolving pharmaceuticals marketplace.

PBMI is hosting its 25th Anniversary National Conference March 2 to March 4 at the Rosen Shingle Creek Hotel in Orlando, FL. PBMI’s yearly conference has been a staple to pharmacy benefit management (PBM), offering an open forum for the exchange of ideas, learning new practices, and networking with peers and key health care stakeholders. 

“It’s evident that health care is changing, and pharmacy management will continue to play a pivotal role in the years ahead to drive change,” explained PBMI. “Each year, our conference brings industry thought leaders to educate attendees on hot topics/strategies influencing the marketplace.”

Returning to the conference this year are George Hill of Deutsche Bank, Doug Long of IQVIA, and Steve Pearson, MD, MSc, of the Institute for Clinical and Economic Review, among others. 

PBMI’s 2020 National Conference is comprised of a multitude of sessions broken down by four different tracks: (1) Contracting & Industry Relations; (2) Innovation & Technology; (3) Clinical & Trend Management; and (4) Designing the Drug Benefit. Several of the included sessions offer continuing education credit for pharmacists. Attendees will be given codes during each session. 

As a preview, First Report Managed Care has compiled an abridged overview of the meeting and the educational sessions offered that would best serve managed care professionals attending the conference. Please refer to the final program and meeting website (www.pbmi.com/AC20) for a complete of sessions, workshops, exhibitors, and other conference events.

HIGHLIGHTED SESSIONS

Monday, March 2, 2020
2:15 – 3:15 PM
Wall Street’s Outlook on the PBM Industry

George Hill, managing director, equity research analyst, Deutsche Bank Securities, shares with attendees his latest perspectives of Wall Street on the PBM landscape. Attendees will also learn about the issues affecting PBMs, and their role in the health care supply chain.

4:00 – 4:50 PM
Pay for Performance: A New PBM Model That’sRevolutionizing the Industry

Hugh Gallagher, PharmD, vice president, business development, BeneCard PBF, will discuss with attendees how a pay-for-performance PBM model can improve health outcomes and reduce overall drug spending by promoting responsible prescription drug utilization and robust, patient-centered clinical programs

4:55 – 5:55 PM
The US Pharmaceutical Market: Trends, Issues, and Outlook

Doug Long, vice president industry relations, IQVIA, will presents data on current trends and issues in health care. Attendees will learn more about what can be expected in the future for the pharmaceutical and pharmacy market. 

Tuesday, March 3, 2020

8:30 – 9:15 AM
The 25 Year PBM Shift: How PBM’s Have Managed Drug Trend…Then & Now

Patty Taddei-Allen, PharmD, MBA, senior director, clinical analytics, and Nick Page, PharmD, chief pharmacy officer, both from WellDyneRx, will provide a look back through history, with how PBMs began to manage drug spend, and how certain trend management tactics have begun to re-emerge.

9:15 –10:00 PM 
Leveraging Integrated Data to Address High-Cost Conditions, Control Drug Spend and Promote a Better Member Experience

Karen Coderre, PharmD, BCPP, director of pharmacy clinical and quality management, Blue Cross Blue Shield North Carolina and Libby Johnson, senior vice president, client success, Pharmaceutical Strategies Group, will provide a look back through history, with how PBMs began to manage drug spend, and how certain trend management tactics have begun to re-emerge. 

1:15 – 2:15 PM
Identifying At-Risk Members for Chronic Conditions and Helping Them Navigate Care and Comorbidities 

Stella Wong, senior director, product development, Transform Care SG&A, CVS Health, will discuss the current challenges and successes managing member’s diabetes, how to leverage advanced analytics to identify members most in need of support, and explore new interventions for at risk members. 

4:00 – 4:45 PM 
What’s Trending in Pharmacy: 2020 and Beyond 

David Calabrese, RPh, MHP, senior vice president & chief pharmacy officer, OptumRx, will speak to attendees about innovative consumer and client strategies that address affordability barriers, patient impact of precision medicine and management tactics, and new pharmacotherapy advancements. 

Wednesday, March 4, 2020

8:30 – 9:30 AM
The Future of Healthcare: Simple, Affordable, Predictable 

Steve Miller, MD, chief clinical officer, Cigna, will discuss health care spend and affordability challenges for patients, payers, and health plans. Attendees of Dr Miller’s session will learn about a path to a future of health care that is simple, affordable, and predictable. 

9:40 – 10:40  AM 
Employer Focused Purchaser Assessment Tool for Value Based Healthcare 

F Randy Vogenberg, PhD, FASHP, board chair, Employer-Provider Interface Council of the Hospital Quality Foundation, and Richard H Bullard, RPh, advisor-fellow, Employer-Provider Interface Council of the Hospital Quality Foundation will explore the current decision landscape using existing example(s) to reduce total costs of care, examine clinical and financial aspects of benefit decision-making, and discuss how to prepare a strategy for specialty drugs across medical and pharmacy benefit plans.

11:10 – 12:10 PM
Advances in At-Home Care Achieving More Personalized, Effective Pharmaceutical Interventions 

Yasmin Samra, PharmD, staff vice president, Pharmacy Product Strategy Development, IngenioRx, will discuss how  patients adherence to treatment is key to managing their condition, consumer convenience solutions that drive better health at home, how digital innovations help activate patient engagement, and how to take a more proactive approach to managing the costs associated with chronic disease.